Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Group 1: Investment Activity of Duquesne Family Office - Duquesne Family Office's billionaire chief, Stanley Druckenmiller, sold all shares of Palantir Technologies in favor of Teva Pharmaceutical Industries, which has seen a 142% increase in stock price over two years [1][15] - Druckenmiller's exit from Palantir was notable as he had previously increased his stake in the company, indicating a significant shift in investment strategy [6][7] - The decision to divest from Palantir may be attributed to profit-taking, concerns over potential defense spending cuts, the risk of an AI bubble burst, and unsustainable valuation with a price-to-sales ratio of 108 [10][11][12][13] Group 2: Teva Pharmaceutical Industries - Teva Pharmaceutical Industries has undergone a significant turnaround, with shares increasing by 142% over the past two years, driven by strategic management changes and resolution of opioid litigation [15][17] - The company has improved its balance sheet, reducing net debt from over $35 billion to less than $15 billion through asset sales and cost-cutting measures [18] - Teva is shifting focus towards novel drug development, which offers higher margins, with products like the tardive dyskinesia drug Austedo projected to generate $2 billion in sales this year [19] - Despite the stock's rise, Teva remains historically undervalued with a forward price-to-earnings ratio of 6.5, indicating potential for further growth [20]